To include your compound in the COVID-19 Resource Center, submit it here.

ABT-450 plus ritonavir/ombitasvir regulatory update

AbbVie and Enanta said EMA accepted for review a pair of MAAs for AbbVie’s all-oral HCV regimen comprising ABT-450 plus the company’s

Read the full 228 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE